FDA: Young-blood transfusions provide ‘no proven clinical benefit’ for aging, Alzheimer’s
he quest to rejuvenate aging people with the blood of young donors has generated paying customers, captured the popular imagination, and, now, prompted a warning from the Food and Drug Administration.
The agency on Tuesday said in a statement that plasma infusions from young people provide “no proven clinical benefit” against normal aging, Alzheimer’s disease, or a host of other diseases — despite a surge in their promotion for those purposes. And, like any other plasma product, young-blood transfusions can pose risks, according to the FDA’s statement, which was attributed to Commissioner Scott Gottlieb and Peter Marks, the director of the agency’s Center for Biologics Evaluation and Research.
The FDA’s warning marked the sharpest rebuke to date of an industry that’s gained steam in the past few years even as mainstream scientists have urged caution. [...]aging bioethics clinical research fda human tissue public health regulation research